These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21470310)

  • 1. Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients.
    Toledo AH; Hendrix L; Buchholz V; Fisher E; Newton K; Smith C; Gerber DA
    Clin Transplant; 2012; 26(1):156-63. PubMed ID: 21470310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
    Sterneck M; Settmacher U; Ganten T; Sarrazin C; Speidel N; Broering D; Heyne N; Paulus E; Mertens M; Fischer L
    Transplant Proc; 2014; 46(1):234-40. PubMed ID: 24507058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
    Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
    Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
    J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
    Lopez-Solis R; DeVera M; Steel J; Fedorek S; Sturdevant M; Hughes C; Humar A
    Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Chan L; Mulgaonkar S; Walker R; Arns W; Ambühl P; Schiavelli R
    Transplantation; 2006 May; 81(9):1290-7. PubMed ID: 16699457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
    Doria C; Ramirez CB; Frank AM; Vaccino S; Fraser N; Marino IR
    Clin Transplant; 2009; 23(6):882-6. PubMed ID: 19573090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.
    Langone AJ; Chan L; Bolin P; Cooper M
    Transplantation; 2011 Feb; 91(4):470-8. PubMed ID: 21245794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
    Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
    Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
    Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects.
    Robaeys G; Cassiman D; Verslype C; Monbaliu D; Aerts R; Pirenne J; Nevens F
    Transplant Proc; 2009 Mar; 41(2):610-3. PubMed ID: 19328938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.
    Bolin P; Tanriover B; Zibari GB; Lynn ML; Pirsch JD; Chan L; Cooper M; Langone AJ; Tomlanovich SJ
    Transplantation; 2007 Dec; 84(11):1443-51. PubMed ID: 18091520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study.
    Dumortier J; Gagnieu MC; Salandre J; Guillaud O; Guillem P; Adham M; Boillot O
    Liver Transpl; 2006 Sep; 12(9):1342-6. PubMed ID: 16741931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bunnapradist S; Sampaio MS; Wilkinson AH; Pham PT; Huang E; Kuo HT; Anastasi B; Danovitch GM; Lo SK
    Am J Nephrol; 2014; 40(2):184-90. PubMed ID: 25196230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
    Burg M; Säemann MD; Wieser C; Kramer S; Fischer W; Lhotta K
    Transplant Proc; 2009 Dec; 41(10):4159-64. PubMed ID: 20005359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
    Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.